Society of Hematologic Oncology

Society of Hematologic Oncology SOHO is the only global society dedicated to the research & treatment of hematologic malignancies. Join SOHO for FREE today at soho.click/join.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with six vot

ing members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

Partnership expands access to CLL treatment in low-, middle-income countries
08/20/2026

Partnership expands access to CLL treatment in low-, middle-income countries

An initiative between BeOne Care Foundation and The Max Foundation has been renewed through 2028 to expand global access to zanubrutinib (Brukinsa) for patients with chronic lymphocytic leukemia in low- and middle-income countries. In a press release by BeOne Medicines, the company announced the con...

08/20/2026

Time is running out to register for . Register today at soho.click/register

Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN
08/20/2026

Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

CD123–directed chimeric antigen receptor T-cell therapy was feasible with a favorable safety profile for patients with relapsed or refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm, including those with prior allogeneic hematopoietic stem cell transplant, according ...

08/14/2026

CD19 CAR T-cell therapy in B-cell ALL: who's a candidate, and when should you refer? Dr. Jae Park explains why patients with even small amounts of residual disease may be candidates for CD19 CAR T-cell therapy. Earlier conversations about CAR T could mean better outcomes for patients.

Listen: https://www.sohoonline.org/SOHO/Education/SOHO-Spotlight-Podcasts.aspx

NICE recommends acalabrutinib for   &
08/12/2026

NICE recommends acalabrutinib for &

The National Institute for Health and Care Excellence (NICE) has recommended acalabrutinib (Calquence) in combination with bendamustine and rituximab for untreated adults not eligible for stem cell transplants diagnosed with mantle cell lymphoma. Additionally, the agency also recommended acalabrutin...

"MD Anderson has been a wonderful environment for drug and therapeutic development. It’s a unique institution because it...
08/07/2026

"MD Anderson has been a wonderful environment for drug and therapeutic development. It’s a unique institution because it’s large enough to allow faculty to focus on a single disease," Dr. William Wierda said in our next Pathways & Perspectives interview on SOHO Insider.

Read the full interview here:

William Wierda, MD, PhD, is a professor of medicine and center medical director for the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. For the past 25 years he has focused on CLL research and treatment. This interview has been edited for len...

Less walking. More talking.That’s one of the things attendees ❤️ most about  . Our intimate meeting format means less ti...
08/05/2026

Less walking. More talking.

That’s one of the things attendees ❤️ most about . Our intimate meeting format means less time navigating convention halls & more time to learn & network.

Register at soho.click/2026 before August 5 for best rates! SOHO members always receive a discount. Become a member at soho.click/join.

Address

The Woodlands, TX
77393

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Society of Hematologic Oncology:

Shortcuts

Featured

Share